Get the Stockscreener App
43.21
3.61%
0.83
Vtv Therapeutics Inc stock is traded at $43.21, with a volume of 28,767.
It is up +3.61% in the last 24 hours and up +60.55% over the past month.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
See More
Previous Close:
$42.38
Open:
$43.32
24h Volume:
28,767
Relative Volume:
2.76
Market Cap:
$169.73M
Revenue:
$17,000
Net Income/Loss:
$-23.87M
P/E Ratio:
-13.85
EPS:
-3.12
Net Cash Flow:
$-22.03M
1W Performance:
+12.65%
1M Performance:
+60.55%
6M Performance:
+191.37%
1Y Performance:
+198.26%
1-Day Range:
$40.77
$44.00
1-Week Range:
$38.22
$44.00
52-Week Range:
$13.20
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
43.10 | 166.89M | 17,000 | -23.87M | -22.03M | -3.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.21 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.83 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.25 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.32 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.76 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | TD Cowen | Buy |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
Is vTv Therapeutics Inc. stock supported by innovation pipeline2026 world cup usa national team group stage goalkeepers build up play knockout prediction statistical analysis - Улправда
TD Cowen Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? - inkl
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
VTVT: TD Cowen Initiates Coverage with a Buy Rating and $67 Pric - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at TD Cowen - MarketBeat
This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
vTv Therapeutics stock initiated with Buy rating at TD Cowen By Investing.com - Investing.com Canada
How Vtv Therapeutics Inc. (VTVT) Affects Rotational Strategy Timing - Stock Traders Daily
Will vTv Therapeutics Inc. (5VT0) stock test record highs in 2025Bullish Engulfing Patterns & Outstanding Growth Opportunities - bollywoodhelpline.com
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen - MarketBeat
Discipline and Rules-Based Execution in VTVT Response - Stock Traders Daily
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
vTv Therapeutics stock price target raised to $47 from $36 at H.C. Wainwright - Investing.com Canada
How vTv Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Highlights & Weekly Stock Breakout Alerts - Улправда
Can vTv Therapeutics Inc. stock double in next 5 yearsJuly 2025 Levels & Real-Time Market Trend Scan - Улправда
Will vTv Therapeutics Inc. (5VT0) stock announce special dividend2025 Pullback Review & Free Technical Pattern Based Buy Signals - Улправда
How vTv Therapeutics Inc. stock performs in interest rate cyclesWeekly Market Report & Consistent Income Trade Ideas - Улправда
What technical charts say about vTv Therapeutics Inc. stock2025 Price Action Summary & Low Drawdown Momentum Ideas - Улправда
EV Market: How vTv Therapeutics Inc. stock valuations compare to rivals2025 Technical Overview & Consistent Income Trade Recommendations - moha.gov.vn
HC Wainwright & Co. Raises Price Target for VTVT to $47 | VTVT S - GuruFocus
HC Wainwright & Co. Maintains vTv Therapeutics (VTVT) Buy Recommendation - Nasdaq
Is vTv Therapeutics Inc. stock recession proof2025 AllTime Highs & Low Risk High Win Rate Picks - DonanımHaber
We're Interested To See How vTv Therapeutics (NASDAQ:VTVT) Uses Its Cash Hoard To Grow - Yahoo Finance
Why vTv Therapeutics Inc. (5VT0) stock appeals to dividend investorsJuly 2025 Update & Fast Momentum Stock Entry Tips - DonanımHaber
Aug Sentiment: What hedge fund activity signals for vTv Therapeutics Inc stock2025 Support & Resistance & Technical Pattern Based Signals - moha.gov.vn
Rally Mode: How vTv Therapeutics Inc. stock reacts to global recession fearsTrade Exit Report & Weekly Breakout Stock Alerts - Улправда
vTv Therapeutics submits protocol for phase 2 diabetes drug trial By Investing.com - Investing.com South Africa
VTVT FinancialsIncome Statement - Quiver Quantitative
vTv Therapeutics submits protocol for phase 2 diabetes drug trial - Investing.com India
vTv Therapeutics Announces Phase 2 Clinical Study for Cadisegliatin in Type 2 Diabetes in Collaboration with M42’s IROS - Quiver Quantitative
vTv Therapeutics and M42’s IROS Announce Submission of - GlobeNewswire
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health - Sahm
Will vTv Therapeutics Inc. (5VT0) stock hit Wall Street targets2025 Trading Volume Trends & Reliable Price Breakout Signals - Улправда
vTv Therapeutics Earnings Notes - Trefis
Investment Report: Is vTv Therapeutics Inc stock oversold or undervaluedJuly 2025 Short Interest & Low Drawdown Trading Techniques - moha.gov.vn
(VTVT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
vTv Therapeutics’ Promising Phase 3 Study on Cadisegliatin for Type 1 Diabetes - MSN
Alzheimer’s Disease Market in the 7MM is USD 5,048 million in 2025, analyses DelveInsight - The Globe and Mail
Does vTv Therapeutics (VTVT) Have the Potential to Rally 25.17% as Wall Street Analysts Expect? - MSN
Big Money Moves: Why vTv Therapeutics Inc stock remains a top recommendation - moha.gov.vn
vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Why vTv Therapeutics Inc. stock remains a top recommendationM&A Rumor & High Accuracy Swing Trade Signals - Newser
What makes vTv Therapeutics Inc. (5VT0) stock appealing to growth investorsWeekly Profit Summary & Consistent Income Trade Ideas - Newser
How vTv Therapeutics Inc. (5VT0) stock moves in volatile trading sessionsJuly 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - Newser
Can vTv Therapeutics Inc. (5VT0) stock hit consensus price targetsMarket Risk Analysis & Long-Term Safe Investment Ideas - Newser
Why vTv Therapeutics Inc. stock is a must watch in 20252025 Key Highlights & High Accuracy Buy Signal Tips - Newser
Is vTv Therapeutics Inc. stock resilient to inflationSell Signal & Stock Market Timing Techniques - Newser
Analysts Are Bullish on Top Healthcare Stocks: vTv Therapeutics (VTVT), Theravance Biopharma (TBPH) - The Globe and Mail
How dovish Fed policy supports vTv Therapeutics Inc. (5VT0) stockTrade Ideas & Free Verified High Yield Trade Plans - Newser
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):